


PHARMACEUTICAL 2019



GALECTIN THERAPEUTICS INC Rank 279 of 363





PHARMACEUTICAL 2019



GALECTIN THERAPEUTICS INC Rank 279 of 363

The relative strengths and weaknesses of GALECTIN THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GALECTIN THERAPEUTICS INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 57% points. The greatest weakness of GALECTIN THERAPEUTICS INC is the variable Net Income, reducing the Economic Capital Ratio by 149% points.

The company's Economic Capital Ratio, given in the ranking table, is -37%, being 73% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	8,832
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	0
Liabilities, Non-Current	0
Other Assets	174
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	2,108
Other Net Income	-298
Other Revenues	0
Property and Equipment	0
Research and Development	6,471
Selling, General and Administrative Expense	7,131

Output Variable	Value in 1000 USD
Assets	9,006
Liabilities	2,108
Expenses	13,602
Revenues	0
Stockholders Equity	6,898
Net Income	-13,900
Comprehensive Net Income	-13,900
Economic Capital Ratio	-37%

